Savara reports first quarter financial results and provides business update

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending march 31, 2023 and provided a business update. “in june of this year, we expect the pivotal phase 3 impala-2 trial to be fully enrolled, therefore, we remain on-track to report top line safety and efficacy data by the end of 2q 2024,” said matt pauls, chair and ceo, savara. “importantly, we believe we.
SVRA Ratings Summary
SVRA Quant Ranking